Method for the generation of compact tale-nucleases and uses thereof

Abstract

The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.

1 - 77 . (canceled) 
     
     
         78 . A compact Transcription Activator-Like Effector Nuclease (TALEN) monomer that cleaves a DNA target sequence of interest comprising:
 (i) one core TALE scaffold comprising Repeat Variable Dipeptide regions (RVDs) designed to target a binding site on said DNA target sequence of interest; and   (ii) at least one engineered single chain meganuclease variant comprising at least two LAGLIDADG homing endonuclease core domains designed to target a binding site on said DNA target sequence of interest, wherein the single chain meganuclease variant is fused to the C- and/or N-terminus of said core TALE scaffold; and   wherein the targeted binding site of the TALE DNA scaffold and the targeted binding site of the meganuclease variant homing endonuclease core domains are separated by 12-40 bases.   
     
     
         79 . The compact TALEN monomer of  claim 78 , wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold. 
     
     
         80 . The compact TALEN monomer of  claim 78 , wherein said single chain meganuclease variant is fused to the N-terminus of said core TALE scaffold. 
     
     
         81 . The compact TALEN monomer of  claim 78 , wherein said single chain meganuclease variant has at least 95% sequence identity with SEQ ID NO: 1. 
     
     
         82 . The compact TALEN monomer of  claim 78 , wherein said core TALE scaffold comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 134 and SEQ ID NO: 135. 
     
     
         83 . The compact TALEN monomer of  claim 78 , wherein said core TALE scaffold comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 136 to SEQ ID NO: 139. 
     
     
         84 . The compact TALEN monomer of  claim 78 , wherein said compact TALEN monomer is designed to target a sequence in a T cell receptor gene. 
     
     
         85 . The compact TALEN monomer of  claim 78 , wherein said compact TALEN monomer comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group of SEQ ID NO: 444-446. 
     
     
         86 . The compact TALEN monomer of  claim 78 , wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold with a peptide linker. 
     
     
         87 . The method of  claim 78 , wherein the DNA target sequence of interest comprises SEQ ID NO: 290. 
     
     
         88 . A compact TALEN monomer that cleaves a DNA target sequence of interest comprising:
 (i) one core TALE scaffold comprising Repeat Variable Dipeptide regions (RVDs) designed to target a binding site on said DNA target sequence of interest; and   (ii) at least one engineered single chain CreI meganuclease variant that has at least 90% identity with SEQ ID NO:291 and is designed to target a binding site on said DNA target sequence of interest fused to the C- and/or N-terminus of said core TALE scaffold; and   wherein the targeted binding site of the TALE DNA binding domain and the targeted binding site of the meganuclease variant binding domain are separated by 12-40 bases.   
     
     
         89 . The compact TALEN monomer of  claim 88 , wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold. 
     
     
         90 . The compact TALEN monomer of  claim 88 , wherein said single chain meganuclease variant is fused to the N-terminus of said core TALE scaffold. 
     
     
         91 . The compact TALEN monomer of  claim 88 , wherein said single chain meganuclease variant has at least 95% sequence identity with SEQ ID NO: 1. 
     
     
         92 . The compact TALEN monomer of  claim 88 , wherein said core TALE scaffold comprises a protein sequence having at least 80% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 134 and SEQ ID NO: 135. 
     
     
         93 . The compact TALEN monomer of  claim 88 , wherein said core TALE scaffold comprises a protein sequence having at least 80% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 136 to SEQ ID NO: 139. 
     
     
         94 . The compact TALEN monomer of  claim 88 , wherein said compact TALEN monomer comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group of SEQ ID NO: 444-446. 
     
     
         95 . The compact TALEN monomer of  claim 88 , wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold with a peptide linker.